Product Name?: (1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one (Edoxaban Impurity 80)
?CAS No.?: 139893-81-5

?? ?Product Overview?
A critical pharmaceutical intermediate used in synthesizing ?Edoxaban? (CAS 480449-70-5), a direct oral anticoagulant (DOAC) for preventing stroke and systemic embolism in atrial fibrillation patients. With a purity of ?≥97%? (HPLC-certified), it ensures precise quality control in API manufacturing and R&D for next-generation anticoagulants. Available in bulk quantities (1kg–25kg) with industrial-grade packaging options.

?? ?Key Advantages?
? ?High Purity?: ≥97% (HPLC/GC-certified), minimizing batch variability in API production.
?? ?Custom Packaging?: Flexible formats (1kg, 5kg, 25kg) for lab and industrial-scale needs.
?? ?Strategic Relevance?: Core intermediate for Edoxaban, a $1.2B+ market drug with expanding cardiovascular applications.

?? ?Applications?

1. ?Anticoagulant Production?: Essential for Edoxaban API synthesis.

2. ?Pharmaceutical R&D?: Supports development of novel thrombin inhibitors.

3. ?Global Supply?: Exported for chemical reagents and generic drug manufacturing.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, NMR, and mass spectrometry.

• ?Compliance?: Meets ISO 9001 and ICH guidelines for intermediates.

?? ?Market Trends?
Demand for Edoxaban intermediates is surging due to ?patent expirations? (2024–2026) and rising global prevalence of cardiovascular diseases. The DOAC market is projected to grow at ?8.4% CAGR? (2025–2030), with Asia-Pacific dominating generic API production. Suppliers offering ?GMP-compliant batches? are prioritized by manufacturers targeting cost-effective anticoagulant solutions.